The EVOQUE Tricuspid Valve Replacement System is an innovative transcatheter therapy for patients with symptomatic severe tricuspid regurgitation who lack effective treatment options. Its transfemoral delivery system provides controlled navigation, while multiple valve sizes ensure anatomical compatibility. EVOQUE demonstrates consistent TR reduction, supported by TRISCEND II data showing over ninety-five percent achieved mild or less TR at one year. The system enables efficient procedures and delivers meaningful improvements in quality of life, functional status, and symptoms. With strong safety outcomes and durable clinical benefit, EVOQUE represents a major advancement in treating severe tricuspid disease.